SARM1 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-9001R-Cy5.5 |
| Product Name | SARM1 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
IF(IHC-P)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human SARM1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 23098 |
| Swiss Prot | Q6SZW1 |
| Synonyms | SARM; SAMD2; MyD88-5; Sterile alpha and TIR motif-containing protein 1; Sterile alpha and Armadillo repeat protein; Sterile alpha motif domain-containing protein 2; SAM domain-containing protein 2; Tir-1 homolog; SARM1; KIAA0524 |
| Background | Negative regulator of MYD88- and TRIF-dependent toll-like receptor signaling pathway which plays a pivotal role in activating axonal degeneration following injury. Promotes Wallerian degeneration an injury-induced axonal death pathway which involves degeneration of an axon distal to the injury site. Can activate neuronal death in response to stress. Regulates dendritic arborization through the MAPK4-JNK pathway. Involved in innate immune response. Inhibits both TICAM1/TRIF- and MYD88-dependent activation of JUN/AP-1, TRIF-dependent activation of NF-kappa-B and IRF3, and the phosphorylation of MAPK14/p38. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |